On Tuesday, Replimune Group (NASDAQ:REPL) saw its price target increased by Jefferies to $19.00, up from the previous target of $16.00. The investment firm has maintained a "Buy" rating on the stock. According to InvestingPro data, the stock has shown remarkable momentum with a 149% return over the past six months, while maintaining a strong balance sheet with more cash than debt.
The adjustment follows the company's recent submission of a Biologics License Application (BLA) under the Accelerated Approval (AA) pathway for its RP1 combined with nivolumab treatment in advanced melanoma patients who have not responded to PD-1 inhibitors. With a market capitalization of $902 million and a current Fair Value assessment from InvestingPro, the stock appears slightly overvalued at current levels.
The analyst from Jefferies highlighted that the submission could lead to a swift approval in 2025. The company's RP1 has received Breakthrough Therapy Designation (BTD), which emphasizes its clinical efficacy and safety compared to existing treatments, as well as the high unmet medical need it addresses. The firm has increased the probability of success (POS) in its valuation model, which contributed to the raised price target.
Replimune anticipates a response regarding the BLA acceptance and a Prescription Drug User Fee Act (PDUFA) date within 74 days. The ongoing enrollment for the Phase 3 confirmatory trial of RP1 is in line with the requirements for the Accelerated Approval decision, supporting the company's regulatory strategy.
The analyst's comments provided further detail on the decision to raise the price target: "We increase POS and raise PT to $19." This statement underscores the analyst's optimism about Replimune's prospects following the company's strategic regulatory submissions and the potential for RP1's approval.
In other recent news, Replimune Group has made noteworthy strides in its business operations and clinical trials. The biotechnology firm recently amended its Sales Agreement with Leerink Partners, decreasing the maximum aggregate offering amount from $100 million to $89 million, and proposed a public offering of $125 million in common stock and pre-funded warrants.
The company has also seen significant advancements with its melanoma treatment candidate, RP1, leading to an Outperform rating by BMO Capital Markets and increased price target. Analyst firms such as H.C. Wainwright and Roth/MKM have maintained their Buy ratings on Replimune following these developments.
Replimune's RP1 has been granted a Breakthrough Therapy designation by the FDA based on its observed safety and clinical activity in the IGNYTE clinical trial's anti-PD1 failed melanoma cohort. The company is currently enrolling patients for the confirmatory Phase 3 IGNYTE-3 trial for RP1. In addition, Madhavan Balachandran has been appointed to its Board of Directors.
Furthermore, Replimune has applied for FDA approval for its advanced melanoma treatment, RP1, in combination with nivolumab. This Biologics License Application (BLA) submission occurred under the FDA's Accelerated Approval pathway. This development has led to reiterated Buy ratings and a $17.00 price target on Replimune's stock from firms such as H.C. Wainwright, BMO Capital, and Roth/MKM.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.